Showing 301-310 of 7617 results for "".
Janssen Approvals, New Thermage FLX, Restylane Silk Cannulas
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-janssen-approvals-new-thermage-flx-restylane-silk-cannulas/18401/Janssen Biotech's Stelara is now approved for the treatment of adolescents 12 years of age or older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Janssen's SIMPONI ARIA® cleared for the treatment of adults with active psoriatic arthritis or activeThe Clinical Significance of Gene Expression Profile Testing for Melanoma
https://practicaldermatology.com/topics/practice-management/the-clinical-significance-of-gene-expression-profile-testing-for-melanoma/20647/Accumulated evidence on GEP Classification suggests that it provides clinically relevant information that can influence patient management for the better.L'Oreal Nabs CeraVe, Smart Beauty Tools, Skin Cancer Knowledge Lacking
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-l-oreal-nabs-cerave-smart-beauty-tools-skin-cancer-knowledge-lacking/18703/Researchers from La Roche-Posay and the George Washington University Department of Dermatology find that citizens in Australia, Ireland, Brazile, and Greece are best educated about UV exposure risks. Americans scored about average, said study author Dr. Adam Friedman. Valeant has agreed to sell itsUse Content Curation to Increase Your Dermatology Marketing Impact
https://practicaldermatology.com/topics/practice-management/use-content-curation-to-increase-your-dermatology-marketing-impact/20987/Curating the right type of content, tailoring it, and adding value to it can produce excellent SEO benefits.Current Sunscreen Controversies Impeding Patient Compliance
https://practicaldermatology.com/topics/practice-management/current-sunscreen-controversies-impeding-patient-compliance/20992/Patient concerns should not prevent the physician from advising adequate sunscreen use.The Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market availTopical Treatment Considerations for Psoriasis
https://practicaldermatology.com/topics/psoriasis/topical-treatment-considerations-for-psoriasis/18845/Jerry Bagel, MD and Neil J. Korman, MD discuss topical treatment options for treating patients with mild psoriasis. They share insights about the effect of vehicles on compliance, particularly when treating patients with scalp psoriasis.Aging: The Cornerstone of Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/aging-the-cornerstone-of-dermatology/18865/In this edition of Derm Insider, Joseph Jorizzo, MD, Brooke Jackson, MD, and Adam Friedman, MD sit down with host Neal Bhatia, MD to discuss the phenomenon of aging and the ubiquitous role it plays in both the scientific and clinical practice of dermatology. In particular they reflect on the evolutiViewpoints: A New Roadmap in Eczema Care
https://practicaldermatology.com/topics/practice-management/viewpoints-a-new-roadmap-in-eczema-care/21144/New strategies in clinical care and advocacy will be essential in this emerging era of eczema management.Cosentyx Approved, Silver is Bad for Burns
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-approved-silver-is-bad-for-burns/18971/FDA approves the first IL-17 inhibitor for psoriasis—Cosentyx from Noavartis, and new research explains why silver sulfadiazine is bad for burn wounds. Plus, we get an update on the Dermatology Summit and the state of innovation in dermatology, and learn about Phase III trials for Dermira's Cimzia.